281 related articles for article (PubMed ID: 25479818)
21. Pulmonary arterial hypertension.
McLaughlin VV; Davis M; Cornwell W
Curr Probl Cardiol; 2011 Dec; 36(12):461-517. PubMed ID: 22035608
[TBL] [Abstract][Full Text] [Related]
22. Left ventricular dysfunction with pulmonary hypertension: Part 1: epidemiology, pathophysiology, and definitions.
Georgiopoulou VV; Kalogeropoulos AP; Borlaug BA; Gheorghiade M; Butler J
Circ Heart Fail; 2013 Mar; 6(2):344-54. PubMed ID: 23513049
[No Abstract] [Full Text] [Related]
23. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension.
Udeoji DU; Schwarz ER
Ther Adv Respir Dis; 2013 Feb; 7(1):39-49. PubMed ID: 23129569
[TBL] [Abstract][Full Text] [Related]
24. Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension.
Kylhammar D; Persson L; Hesselstrand R; Rådegran G
Scand Cardiovasc J; 2014 Aug; 48(4):223-33. PubMed ID: 24912571
[TBL] [Abstract][Full Text] [Related]
25. Pulmonary hypertension in patients with chronic myeloproliferative disorders.
Adir Y; Elia D; Harari S
Eur Respir Rev; 2015 Sep; 24(137):400-10. PubMed ID: 26324801
[TBL] [Abstract][Full Text] [Related]
26. Managing adult Fontan patients: where do we stand?
Clift P; Celermajer D
Eur Respir Rev; 2016 Dec; 25(142):438-450. PubMed ID: 27903666
[TBL] [Abstract][Full Text] [Related]
27. Treatment of secondary pulmonary hypertension with bosentan after left ventricular assist device implantation.
LaRue SJ; Garcia-Cortes R; Nassif ME; Vader JM; Ray S; Ravichandran A; Rasalingham R; Silvestry SC; Ewald GA; Wang IW; Schilling JD
Cardiovasc Ther; 2015 Apr; 33(2):50-5. PubMed ID: 25759010
[TBL] [Abstract][Full Text] [Related]
28. Role of the endothelium in pulmonary arterial hypertension.
Haworth SG
Vascul Pharmacol; 2006 Nov; 45(5):317-25. PubMed ID: 17005453
[TBL] [Abstract][Full Text] [Related]
29. Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.
Frantz RP; Durst L; Burger CD; Oudiz RJ; Bourge RC; Franco V; Waxman AB; McDevitt S; Walker S
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):550-7. PubMed ID: 24742768
[TBL] [Abstract][Full Text] [Related]
30. An evidence-based approach to the management of pulmonary arterial hypertension.
Archer SL; Michelakis ED
Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
[TBL] [Abstract][Full Text] [Related]
31. [Hemodynamic Definition of Pulmonary Hypertension: Commentary on the Proposed Change by the 6th World Symposium on Pulmonary Hypertension].
Rosenkranz S; Diller GP; Dumitrescu D; Ewert R; Ghofrani HA; Grünig E; Halank M; Held M; Kaemmerer H; Klose H; Kovacs G; Konstantinides S; Lang IM; Lange TJ; Leuchte H; Mayer E; Olschewski A; Olschewski H; Olsson KM; Opitz C; Schermuly RT; Seeger W; Wilkens H; Hoeper MM
Dtsch Med Wochenschr; 2019 Sep; 144(19):1367-1372. PubMed ID: 31277079
[TBL] [Abstract][Full Text] [Related]
32. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.
Keir GJ; Walsh SL; Gatzoulis MA; Marino PS; Dimopoulos K; Alonso R; Raposeiras-Roubin S; Renzoni EA; Maher TM; Wells AU; Wort SJ
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):82-90. PubMed ID: 25078636
[TBL] [Abstract][Full Text] [Related]
33. Chronic thromboembolic pulmonary hypertension--a diagnostic and therapeutic update.
Stricker H
Vasa; 2016; 45(3):195-9. PubMed ID: 27128884
[TBL] [Abstract][Full Text] [Related]
34. Pulmonary arterial hypertension: tailoring treatment to risk in the current era.
Gaine S; McLaughlin V
Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29263175
[TBL] [Abstract][Full Text] [Related]
35. Pulmonary vascular effects of pulsed inhaled nitric oxide in COPD patients with pulmonary hypertension.
Hajian B; De Backer J; Vos W; Van Holsbeke C; Ferreira F; Quinn DA; Hufkens A; Claes R; De Backer W
Int J Chron Obstruct Pulmon Dis; 2016; 11():1533-41. PubMed ID: 27462149
[TBL] [Abstract][Full Text] [Related]
36. Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era.
Savale L; Guignabert C; Weatherald J; Humbert M
Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29653948
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary arterial hypertension: pharmacologic therapies and potential pulmonary artery denervation treatment.
Zhang YJ; Li MH; Chen SL
EuroIntervention; 2013 May; 9 Suppl R():R149-54. PubMed ID: 23732148
[TBL] [Abstract][Full Text] [Related]
38. Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats.
Zhang WH; Liu CP; Zhang YJ; Ji YQ; Lu WX; Zeng Q
Scand Cardiovasc J; 2012 Dec; 46(6):374-80. PubMed ID: 22971207
[TBL] [Abstract][Full Text] [Related]
39. Practical considerations for therapies targeting the prostacyclin pathway.
Farber HW; Gin-Sing W
Eur Respir Rev; 2016 Dec; 25(142):418-430. PubMed ID: 27903664
[TBL] [Abstract][Full Text] [Related]
40. Interpreting risk reduction in clinical trials for pulmonary arterial hypertension.
Lajoie AC; Bonnet S; Lacasse Y; Lega JC; Provencher S
Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29769296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
